{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:03:54Z","timestamp":1786539834184,"version":"build-2736575974"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"unspecified","delay-in-days":133,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Region Stockholm","award":["FoUI-976208 and FoUI-974342"],"award-info":[{"award-number":["FoUI-976208 and FoUI-974342"]}]},{"name":"the Swedish Cancer Society","award":["22 2210 Pj"],"award-info":[{"award-number":["22 2210 Pj"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2021-01293"],"award-info":[{"award-number":["2021-01293"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjph"],"accepted":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The patterns of comorbidities preceding major adverse liver outcomes (MALOs) in metabolic dysfunction-associated steatotic liver disease (MASLD) are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients from the Swedish National Patient Register with MASLD-related MALO between 2006 and 2022 were identified, and matched for age, sex and diagnosis year, with individuals having MASLD without MALO, and population controls. Hierarchical clustering using International Classification of Diseases-10 codes was employed for identifying comorbidities, with comparison between the groups. Median times of comorbidities until MALO were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>996 patients with MASLD-related MALO and median age of 67 years (IQR=60\u201373), of which 49% men, were matched with 3921 individuals with MASLD without MALO and 9056 population controls. A median of nine comorbidity categories was observed in patients with MALO, who exhibited a cardiometabolic cluster with type 2 diabetes (49%) and hypertension (56%), which were diagnosed 6 years before MALO. Heart failure and atrial fibrillation\/flutter preceded MALO in 13% and 14% and were diagnosed 4 years beforehand. Myocardial infarction occurred 6 years prior to MALO in 8%, while angina pectoris developed 8 years prior in 14% of patients. Sleep disorders were seen 8 years before MALO in 14% of patients. All identified comorbidities were present at lower rates in individuals with MASLD without MALO and population controls (p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with MASLD-related MALO are frequently multimorbid. Cardiac disease and sleep disorders, with cardiometabolic risk factors, characterise individuals developing MALO. These patterns may simplify case finding and earlier interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjph-2025-003322","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:55:12Z","timestamp":1763038512000},"page":"e003322","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Temporal comorbidity patterns preceding MASLD-related major adverse liver outcomes: a nationwide population-based case\u2013control study in Sweden"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-5872","authenticated-orcid":false,"given":"Joost","family":"Boeckmans","sequence":"first","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"In Vitro Liver Disease Modelling Team, Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4851-0256","authenticated-orcid":false,"given":"Linnea","family":"Widman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-3497","authenticated-orcid":false,"given":"Rickard","family":"Strandberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-1799","authenticated-orcid":false,"given":"Ying","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-6591","authenticated-orcid":false,"given":"Axel","family":"Wester","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-1759","authenticated-orcid":false,"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2026010703074134000_3.2.e003322.1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.32519","article-title":"Risk of cardiovascular disease and loss in life expectancy in NAFLD","volume":"76","author":"Shang","year":"2022","journal-title":"Hepatology"},{"key":"2026010703074134000_3.2.e003322.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322786"},{"key":"2026010703074134000_3.2.e003322.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"2026010703074134000_3.2.e003322.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026010703074134000_3.2.e003322.7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","volume":"9","author":"Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"61","author":"Owrangi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010703074134000_3.2.e003322.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024"},{"key":"2026010703074134000_3.2.e003322.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5997"},{"key":"2026010703074134000_3.2.e003322.11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"2026010703074134000_3.2.e003322.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.11.006"},{"key":"2026010703074134000_3.2.e003322.13","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"2026010703074134000_3.2.e003322.14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S2468-1253(24)00306-6","article-title":"Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis","volume":"9","author":"Francque","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/00365521.2022.2051202","article-title":"Cohort profile: decoding the epidemiology of liver disease in Sweden (DELIVER)","volume":"57","author":"Hagstr\u00f6m","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"2026010703074134000_3.2.e003322.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100688","article-title":"Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis","volume":"5","author":"Rashidi-Alavijeh","year":"2023","journal-title":"JHEP Rep"},{"key":"2026010703074134000_3.2.e003322.17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.18","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16218","article-title":"MASLD Is Associated With an Increased Long-Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"key":"2026010703074134000_3.2.e003322.19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010703074134000_3.2.e003322.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101171","article-title":"Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study","volume":"6","author":"Boeckmans","year":"2024","journal-title":"JHEP Rep"},{"key":"2026010703074134000_3.2.e003322.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.101153","article-title":"Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study","volume":"48","author":"Boeckmans","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026010703074134000_3.2.e003322.22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.23","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00316-4"},{"key":"2026010703074134000_3.2.e003322.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.050"},{"key":"2026010703074134000_3.2.e003322.25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(24)00313-3","article-title":"Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study","volume":"10","author":"Lindfors","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010703074134000_3.2.e003322.26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc23-1937","article-title":"Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes","volume":"47","author":"Shang","year":"2024","journal-title":"Diabetes Care"},{"key":"2026010703074134000_3.2.e003322.27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962"},{"key":"2026010703074134000_3.2.e003322.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026010703074134000_3.2.e003322.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02824-3","article-title":"Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality","volume":"24","author":"Han","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026010703074134000_3.2.e003322.30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","article-title":"Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden","volume":"83","author":"Issa","year":"2025","journal-title":"J Hepatol"},{"key":"2026010703074134000_3.2.e003322.31","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026010703074134000_3.2.e003322.32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/00365521.2020.1820566","article-title":"Validity of administrative codes associated with cirrhosis in Sweden","volume":"55","author":"Bengtsson","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2026010703074134000_3.2.e003322.33","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2026010703074134000_3.2.e003322.34","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"}],"container-title":["BMJ Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjph-2025-003322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:10:35Z","timestamp":1767784235000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpublichealth.bmj.com\/lookup\/doi\/10.1136\/bmjph-2025-003322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjph-2025-003322"],"URL":"https:\/\/doi.org\/10.1136\/bmjph-2025-003322","relation":{},"ISSN":["2753-4294"],"issn-type":[{"value":"2753-4294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}